Skip to content

ABBOTT LABORATORIES

ABT · XNYS

CIK 1800fmd_1KBDE9BRYH6S97VZZ2P9N27SS4Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2007 to Sep 30, 2026, 76 periods

Latest annual · FY2025

Millions
Total revenues
44,328
Gross profit
25,009
Operating income
8,053
Net income
6,524
Free cash flow
7,395

Latest quarter · Q3 FY2026

Millions
Total revenues
13,013
Gross profit
7,385
Operating income
1,358
Net income
920
Free cash flow
1,224

Daily close · ABTIEX trades only

Nov 13, 2025 to Nov 11, 2026 · 250 sessions

109.38 USD

80100120140Nov 13, 2025May 14, 2026Nov 11, 2026Vol

Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.

Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms

Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2022 to FY2025
+0.5%
Revenue, 5 yearsFY2020 to FY2025
+5.1%
Net income, 5 yearsFY2020 to FY2025
+7.7%

ABBOTT LABORATORIES (ABT) financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2025FY2024ChangeSource
Revenue$44.3 billion$42 billion+5.7%10-K 2026-02-20 · proof
Gross profit$25 billion$23.2 billion+7.6%10-K 2026-02-20 · proof
Operating income$8.1 billion$6.8 billion+18%10-K 2026-02-20 · proof
Net income$6.5 billion$13.4 billion-51.3%10-K 2026-02-20 · proof
Cash from operating activities$9.6 billion$8.6 billion+11.8%10-K 2026-02-20 · proof
Free cash flow$7.4 billion$6.4 billion+16.4%10-K 2026-02-20 · proof
Total assets$86.7 billion$81.4 billion+6.5%10-K 2026-02-20 · proof
Total liabilities$33.9 billion$33.5 billion+1.3%10-K 2026-02-20 · proof
Cash and cash equivalents$8.5 billion$7.6 billion+11.9%10-K 2026-02-20 · proof
Total debt$12.9 billion$14.1 billion-8.5%10-K 2026-02-20 · proof
What was ABBOTT LABORATORIES (ABT)'s revenue in fiscal 2025?
ABBOTT LABORATORIES (ABT) reported revenue of $44.3 billion for fiscal 2025 (the year ended Dec 31, 2025), against $42 billion the year before (+5.7%). Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What was ABBOTT LABORATORIES (ABT)'s gross profit in fiscal 2025?
ABBOTT LABORATORIES (ABT) reported gross profit of $25 billion for fiscal 2025 (the year ended Dec 31, 2025), against $23.2 billion the year before (+7.6%). Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What was ABBOTT LABORATORIES (ABT)'s operating income in fiscal 2025?
ABBOTT LABORATORIES (ABT) reported operating income of $8.1 billion for fiscal 2025 (the year ended Dec 31, 2025), against $6.8 billion the year before (+18%). Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What was ABBOTT LABORATORIES (ABT)'s net income in fiscal 2025?
ABBOTT LABORATORIES (ABT) reported net income of $6.5 billion for fiscal 2025 (the year ended Dec 31, 2025), against $13.4 billion the year before (-51.3%). Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What was ABBOTT LABORATORIES (ABT)'s cash from operating activities in fiscal 2025?
ABBOTT LABORATORIES (ABT) reported cash from operating activities of $9.6 billion for fiscal 2025 (the year ended Dec 31, 2025), against $8.6 billion the year before (+11.8%). Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What was ABBOTT LABORATORIES (ABT)'s free cash flow in fiscal 2025?
ABBOTT LABORATORIES (ABT) reported free cash flow of $7.4 billion for fiscal 2025 (the year ended Dec 31, 2025), against $6.4 billion the year before (+16.4%). Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What are ABBOTT LABORATORIES (ABT)'s total assets?
As of Dec 31, 2025, ABBOTT LABORATORIES (ABT) reported total assets of $86.7 billion, against $81.4 billion a year earlier (+6.5%). Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What are ABBOTT LABORATORIES (ABT)'s total liabilities?
As of Dec 31, 2025, ABBOTT LABORATORIES (ABT) reported total liabilities of $33.9 billion, against $33.5 billion a year earlier (+1.3%). Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What are ABBOTT LABORATORIES (ABT)'s cash and cash equivalents?
As of Dec 31, 2025, ABBOTT LABORATORIES (ABT) reported cash and cash equivalents of $8.5 billion, against $7.6 billion a year earlier (+11.9%). Source: the 10-K filed with the SEC on Feb 20, 2026. SEC
What is ABBOTT LABORATORIES (ABT)'s total debt?
As of Dec 31, 2025, ABBOTT LABORATORIES (ABT) reported total debt of $12.9 billion, against $14.1 billion a year earlier (-8.5%). Source: the 10-K filed with the SEC on Feb 20, 2026. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:ABT&period_type=annual&limit=5"

Information only, not investment advice.